http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2642623-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2eb0b6c7daea4d1592f2503d4fc5b1ab |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-726 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate | 2013-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_132af2049f1a9961e7d10bffdccf7736 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc9f4efd18172277b5055f72eecd93ae |
| publicationDate | 2018-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2642623-C2 |
| titleOfInvention | Method for prediction of risk of malignant neoplasms development or diagnosis of malignant neoplasms in woman |
| abstract | FIELD: medicine. n SUBSTANCE: method for prediction of the risk of breast cancer development in a female individual that does not suffer from breast cancer, includes: determination of the level of pro-neurotensin 1-117 with amino acid sequence represented on SEQ ID No. 5, or its fragments from at least 5 amino acids or peptides containing this pro-neurotensin 1-117, obtained from the biological fluid of the specified female individual, selected from the group consisting of blood, serum, plasma, urine, cerebrospinal fluid and saliva, where pro-neurotensin 1-117 level is determined on an empty stomach; and correlation of the specified level of pro-neurotensin 1-117 or its fragments, or peptides containing pro-neurotensin 1-117, with the risk of breast cancer development, where an elevated level is prognostic for the increased risk of breast cancer. n EFFECT: method allows to effectively predict the risk of breast cancer development in a female individual. n 14 cl, 2 dwg, 10 tbl, 5 ex |
| priorityDate | 2012-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 147.